These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 21057493)

  • 1. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
    Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
    Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
    Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
    Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
    Soura EN; Karikas GA
    J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
    Gjini E; Mansour MR; Sander JD; Moritz N; Nguyen AT; Kesarsing M; Gans E; He S; Chen S; Ko M; Kuang YY; Yang S; Zhou Y; Rodig S; Zon LI; Joung JK; Rao A; Look AT
    Mol Cell Biol; 2015 Mar; 35(5):789-804. PubMed ID: 25512612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
    Pronier E; Almire C; Mokrani H; Vasanthakumar A; Simon A; da Costa Reis Monte Mor B; Massé A; Le Couédic JP; Pendino F; Carbonne B; Larghero J; Ravanat JL; Casadevall N; Bernard OA; Droin N; Solary E; Godley LA; Vainchenker W; Plo I; Delhommeau F
    Blood; 2011 Sep; 118(9):2551-5. PubMed ID: 21734233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insight into substrate preference for TET-mediated oxidation.
    Hu L; Lu J; Cheng J; Rao Q; Li Z; Hou H; Lou Z; Zhang L; Li W; Gong W; Liu M; Sun C; Yin X; Li J; Tan X; Wang P; Wang Y; Fang D; Cui Q; Yang P; He C; Jiang H; Luo C; Xu Y
    Nature; 2015 Nov; 527(7576):118-22. PubMed ID: 26524525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
    Poole CJ; Lodh A; Choi JH; van Riggelen J
    Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH2 regulates U2AF1 expression and hydroxymethylation in MDS patients.
    Cheng H; Liu Y; Cheng M; Li W; Sun M; Tang Q; Ma J; Li P; Gong T
    Biotechnol Genet Eng Rev; 2024 Oct; 40(2):788-799. PubMed ID: 36942631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.